相关实验视频

Updated: Jul 11, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

扭矩天诺病毒血DNA负载:在CAR-T疗法中是一种新的预后生物标志物

Ana Benzaquén¹, Estela Giménez², Gloria Iacoboni^3,4

¹Haematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.

Bone marrow transplantation

|November 3, 2023

概括

扭矩天诺病毒 (TTV) 监测预测了仿真抗原受体T细胞 (CAR-T) 治疗结果. 神经毒性开始时较低的TTV DNA水平表明严重的免疫效应细胞相关的神经毒性综合征风险,而降低的TTV水平与更好的生存相关.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

扭矩病毒 (TTV) 是一种DNA病毒,被认为是免疫能力的标记物,特别是在移植中.
化学抗原受体T细胞 (CAR-T) 疗法是复发或耐火性大B细胞淋巴瘤的关键治疗方法.

研究的目的:

在CAR-T治疗期间调查Torque Teno Virus (TTV) DNA动态.
评估TTV水平与CAR-T相关毒性,治疗反应和生存结果的相关性.

主要方法:

在接受CAR-T治疗的79名成年患者中监测了血TTVDNA水平.
进行了统计分析,以评估TTV DNA负载与免疫效应细胞相关的神经毒性综合征 (ICANS),无进展生存率和整体生存率之间的相关性.

主要成果:

TTV DNA 负载最初在淋巴损失后下降,然后在第90天增加.
在ICANS开始时,TTV DNA负载低于4.05 log10 副本/毫升,预测严重的ICANS (或16.68).
在淋巴缺血和CAR-T输注之间,TTVDNA水平稳定或下降的患者表现出更好的无进展生存率 (HR 0.31).

结论:

在CAR-T治疗期间,等离子体TTVDNA动态作为免疫能力的潜在代用标记.
TTV监测可能有助于预测CAR-T疗效和毒性,并可能指导治疗策略.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.